Literature DB >> 25833308

Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time.

Stefanie Hieke1, Martina Kleber2, Christine König3, Monika Engelhardt3, Martin Schumacher4.   

Abstract

Conditional survival (CS) is defined as the probability of surviving further t years, given that a patient has already survived s years after the diagnosis of a chronic disease. It is the simplest form of a dynamic prediction in which other events in the course of the disease or biomarker values measured up to time s can be incorporated. CS has attracted attention in recent years either in an absolute or relative form where the latter is based on a comparison with an age-adjusted normal population being highly relevant from a public health perspective. In its absolute form, CS constitutes the quantity of major interest in a clinical context. Given a clinical cohort of patients with a particular type of cancer, absolute CS can be estimated by conditional Kaplan-Meier estimates in strata defined, for example, by age and disease stage or by a conditional version of the Cox and other regression models for time-to-event data. CS can be displayed as a function of the prediction time s in parametric as well as nonparametric fashion. We illustrate the use of absolute CS in a large clinical cohort of patients with multiple myeloma. For investigating CS, it is necessary to ensure almost complete long-term follow-up of the patients enrolled in the clinical cohort and to consider potential age-stage migration as well as changing treatment modalities over time. CS provides valuable and relevant information on how prognosis develops over time. It also serves as a starting point for identifying factors related to long-term survival. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25833308     DOI: 10.1158/1078-0432.CCR-14-2154

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA.

Authors:  Ray M Merrill; Erin Johnson
Journal:  J Cancer Surviv       Date:  2017-08-02       Impact factor: 4.442

2.  Conditional Survival Analysis of Metastatic Colorectal Cancer Patients Living ≥24 Months: A Single Institutional Study.

Authors:  Nadia D Ali; Kristen Donohue; Shadi Zandieh; Chunxia Chen; Dirk Moore; Elizabeth Poplin; Mihir M Shah; John Nosher; Bin Gui; Salma K Jabbour; Kristen Spencer; Darren R Carpizo
Journal:  Am J Clin Oncol       Date:  2019-06       Impact factor: 2.339

3.  Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.

Authors:  Monika Engelhardt; Sandra Maria Dold; Gabriele Ihorst; Alexander Zober; Mandy Möller; Heike Reinhardt; Stefanie Hieke; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

4.  Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation.

Authors:  F Lennie Wong; Jennifer Berano Teh; Liezl Atencio; Tracey Stiller; Heeyoung Kim; Dayana Chanson; Stephen J Forman; Ryotaro Nakamura; Saro H Armenian
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

5.  Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Authors:  Johannes M Waldschmidt; Alexander Keller; Gabriele Ihorst; Olga Grishina; Stefan Müller; Dagmar Wider; Anna V Frey; Kristina King; Roman Simon; Annette May; Pierfrancesco Tassone; Justus Duyster; Manfred Jung; Noopur Raje; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

6.  The Optimal Timing of Stage 2 Palliation for Hypoplastic Left Heart Syndrome: An Analysis of the Pediatric Heart Network Single Ventricle Reconstruction Trial Public Data Set.

Authors:  James M Meza; Edward J Hickey; Eugene H Blackstone; Robert D B Jaquiss; Brett R Anderson; William G Williams; Sally Cai; Glen S Van Arsdell; Tara Karamlou; Brian W McCrindle
Journal:  Circulation       Date:  2017-07-07       Impact factor: 29.690

7.  Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.

Authors:  Monika Engelhardt; Gabriele Ihorst; Ola Landgren; Milena Pantic; Heike Reinhardt; Johannes Waldschmidt; Annette M May; Martin Schumacher; Martina Kleber; Ralph Wäsch
Journal:  Haematologica       Date:  2015-07-09       Impact factor: 9.941

8.  What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Authors:  Tao Ji; Wei Guo; Rongli Yang; Xiaodong Tang; Yifei Wang; Lin Huang
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

9.  Synchronous vs. Metachronous Metastases in Adrenocortical Carcinoma: an Analysis of the Dutch Adrenal Network.

Authors:  M H T Ettaieb; J C Duker; R A Feelders; E P M Corssmit; C W Menke-van der Houven van Oordt; H J L M Timmers; M N Kerstens; J W Wilmink; P M Zelissen; B Havekes; H R Haak
Journal:  Horm Cancer       Date:  2016-07-15       Impact factor: 3.869

10.  Association between surgical approach and survival following resection of abdominopelvic malignancies.

Authors:  Tarik K Yuce; Ryan J Ellis; Jeanette Chung; Ryan P Merkow; Anthony D Yang; Nathaniel J Soper; Edward J Tanner; Edward M Schaeffer; Karl Y Bilimoria; Gregory B Auffenberg
Journal:  J Surg Oncol       Date:  2020-01-22       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.